Yesterday (March 18) PureTech Health plc announced the completion of the acquisition of its founded entity, Karuna Therapeutics, Inc., by Bristol Myers Squibb for a staggering $14 billion.
In an encouraging development, neuromodulation, a form of bioelectric medicine, has emerged as a promising avenue for enhancing health by regulating the nervous system.
In a significant move aimed at revolutionizing Central Nervous System (CNS) research, eCOA/ePRO platform provider uMotif has announced a strategic partnership with MoCA Cognition, the creators of a recognized test for early cognitive impairment detection.
Pharma company Mercaptor has announced its new ‘breakthrough’ technology at J.P. Morgan HealthCare Conference which it says could transform Alzheimer's, TBI, and epilepsy treatment.
Positive results of a study into the effects of an add-on to antipsychotics for the management of treatment-resistant schizophrenia (TRS) have been announced by Newron Pharmaceuticals.
Clinical-stage pharma company, PharmaKure which develops precision medicine for Alzheimer’s Disease and other neurological diseases has announced a collaboration agreement with one of the largest comprehensive universities in Malaysia.
A significantly greater improvement in people with depression was achieved after they were given ALT-300, an adjunctive treatment, during a phase 2a study.
Drugs like Annovis Bio’s buntanetap and prasinezumab have the potential to “revolutionize the treatment of Parkinson’s Disease” says analytics company, GlobalData, an analytics company, but it is a complex road ahead.
Sygnature Discovery has launched an in vivo inflammation model, that the company says is ‘exciting but only the beginning’ of understanding life-limiting neuroinflammatory conditions.
Oversubscribed, series B financing for Noema Pharma’s clinical stage assets has been successfully closed raising $112 million from new and existing investors.
A leader from the health tech company explains how voice-based technologies could transform monitoring of patients with dementia, Alzheimer’s, and other conditions.
The US- and Hungary-based pharma firms will work on research, development, and commercialization of dopamine receptor modulators for potential treatments.
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern University’s Shirley Ryan AbilityLab.
The advocacy organization's PIE4CNS initiative is aimed at targeting and reducing gaps in diagnosis, research, and trials for rare neurological conditions.
A representative of the rare-disease specialist firm outlines the unique obstacles of orphan CNS disease research, and how professionals can overcome them.
A leader from the clinical trial technology firm shares how direct data capture and other solutions can address the unique needs of such complex studies.
Amylgen and Neuron-Experts partner to create a comprehensive offering of in-vivo and in-vitro efficacy evaluation for compounds in neurodegenerative diseases.
Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
WIRB-Copernicus Group (WCG) has acquired eConsent technology to help clinical trial volunteers – and their families – make more informed decisions, says CEO.
WIRB-Copernicus Group (WCG) has acquired MedAvante and ProPhase, bolstering the company’s presence in the central nervous system (CNS) and behavioral health assessment markets.
Sanofi and Artificial Intelligence (AI)-driven Exscientia have announced a €250m ($271.9m) drug target research collaboration and licence option agreement.
Private equity fund Apax Partners will take control of Spanish API manufacturer Inke when it completes the acquisition of Invent Farma later this year.
Contract research organization INC Research reported 14.2% net service revenue growth in Q2, compared to the same quarter last year, raised future guidance and saw its stock bump up more than 10%.
Demand for CNS assets will help break records for pharma M&As in 2015, Neel Patel, VP of inVentiv Health consultancy Campbell Alliance, tells in-Pharmatechnologist.com.
CRO INC Research saw its net service revenue increase by 14.5% to $211.5m in Q1, which was considerably higher than analyst expectations and driven by particularly strong growth in trials around CNS (central nervous system), oncology and other complex...
Alkermes has been downgraded by analysts who say the success of its decision to focus on own-brand products and sell its legacy CMO site hinges on its ability to win in already competitive markets.
For the second straight year Charles River Laboratories has seen more of its revenue derived from biotech companies than Big Pharma, CEO James Foster told investors at two conferences on Tuesday and Wednesday.
Following its recent IPO, INC Research delivered double-digit net service revenue growth for the year and further diversified its customer base when compared with previous years.
Contract drug developer Evotec AG has achieved multiple milestones resulting in €8m ($9.8m) in revenue thanks to its collaborations with Bayer and Janssen Pharmaceuticals.
A drug delivery technology that ‘shuttles’ molecules across the blood-brain-barrier could have major implications in developing drugs for disorders such as Alzheimer's and Parkinson’s disease, Roche says.
Icon has boosted its Phase I translational medicine services in Manchester, UK, in preparation for what it believes will be a boom in the drug development area.
Outsourcing-Pharma.com presents its weekly round-up of the latest changes within in the world of pharmaceutical careers, including news from AmerisourceBergen, Aviro and Cellectricon.
Generic API (active pharmaceutical ingredient) makers should consider the off-patent potential of a drug as soon as it is launched, according to a new study by PharmaIntellect.
in-PharmaTechnologist presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Sirona, Hospira, and Biogen Idec.
in-PharmaTechnologist presents its round-up of the latest manufacturing headlines including new facilities for Aptar and Granules, and some good news for Swiss Novartis workers.
